ReviewThe relevance of estrogen/estrogen receptor system on the gender difference in cardiovascular risk
Graphical abstract
Introduction
Thrombosis is the commonest cause of death in developed countries. It is the basis of three major cardiovascular disorders: ischemic heart disease (acute coronary syndrome), stroke (arterial cerebral thrombosis) and venous thromboembolism (VTE). Depending on the various pathological conditions a different incidence of thrombotic events between men and women was found. For instance, stroke incidence appears as lower in females than in males until advanced ages, after which the rates rise dramatically in both sexes [1]. Similarly, the recurrent venous thrombosis appears as less frequent in females and, also for the first event, the male/female ratio is 2:1 [2]. These data seem to suggest that some hormonal factors, estrogen in particular, could protect women from thrombotic events. Several insights derive in fact from a number of studies carried out either in animals or in humans. For example, studies carried out in animal models have demonstrated that ovariectomy increases infarct size and that estradiol supplementation reduces injury [3]. In humans, a good example is that represented by the use of oral contraceptives and postmenopausal hormonal therapies, which contain various estrogens: it has been found that these treatments are associated with a weaker risk of both arterial and venous thrombosis [4]. On these bases, it was hypothesized that hormonal (i.e., estrogenic) factors could play a pivotal role in regulating thrombotic events, also influencing the ensuing cardiovascular diseases. Herein, we discuss literature data dealing with this issue: the role of estrogen and estrogen receptors in determining megakaryocyte/platelet integrity and function and in the control of thrombogenicity.
Section snippets
Hormones and thrombosis
The crucial role of hormones in thrombosis and hemostasis in men and women has been analyzed in several works [2], [5]. These works underscore that, although obviously occurring in both sexes, i) the intrinsic risk of VTE is two-fold higher in men than in women; ii) hormonal contraceptives increase the risk of VTE in women and that iii) this risk varies per type, dose, and hormone administration route. On this basis, avoidance of some hormonal contraceptives (as well as thrombosis prophylaxis
Sex differences in platelet function
Platelets can be activated by circulating factors in the blood or by the sub-endothelial collagen during endothelial injury. The interaction between exposed atherosclerotic plaque components, platelet receptors and coagulation factors eventually leads to platelet activation, aggregation and the subsequent formation of a superimposed thrombus (i.e. atherothrombosis), which may compromise the arterial lumen leading to the presentation of acute ischaemic syndromes [19]. Hormones can influence
Hormones and coagulation
Hormone levels can affect the levels of clotting factors and favor an acquired resistance to the actions of activated protein C, leading to an increased risk of VTE [29]. Decreased levels of von Willebrand factor (VWF), fibrinogen, and activated factor VII have been measured during the menstrual cycle [29]. Conversely, pregnancy is a procoagulant state with progressive increase in levels of factors VII, VIII, X, and XII, fibrinogen, and VWF, as well as increased resistance to activated protein
On the estrogen receptors
The effects of estrogen are mediated in part through the activation of two estrogen receptors: estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). These receptors function as transcription factors regulating the expression of target genes and can be localized in the nucleus, in the plasma membrane or in the mitochondria. Probably, nuclear and non-nuclear estrogen receptors are not separate units, but rather the components of a complex mechanism in which they cooperate with each
Implication of estrogen/ER interactions in megakaryocytopoiesis
Within the bone marrow compartment stem cells differentiate along mesenchymal and hematopoietic lineages regulated by local and systemic factors. Progenitor cells, called megakaryocytes (MKs), produce numerous colony-forming units (CFU-MK) that differentiate and undergo endomitosis with the generation of large cells with lobulated nuclei. During the final stages of maturation, fragmentation of MK cytoplasm leads to the formation of platelets and their release into the circulation [61]. Recent
mERs
Estrogen may modify platelet function through their interaction with ERs. Moro and collaborators showed that E2 (100 nM) determined calcium entry and platelet aggregation in a synergistic way with thrombin (a physiological agonist of platelet aggregation) [75]. In particular, 17β-estradiol caused the rapid phosphorylation of the tyrosine kinases Src and Pyk2 and the formation of a signaling complex, which includes Src, Pyk2, and the phosphatidylinositol 3-kinase. These events were dependent on
MicroRNAs (miRNAs) and hormones
miRNAs are endogenously expressed, small RNAs (sized about 22 nucleotides) representing the most abundant class of regulators of gene expression. MicroRNAs have the ability to target multiple messenger RNAs (mRNAs) with the consequent inhibition of mRNA translation or degradation. Their dysregulated expression profiles associate with several human diseases, including hemostasis and thrombosis [87]. In consequence, microRNAs have been shown to be useful as diagnostic and prognostic indicators of
Conclusions
All in all, literature data underscore the importance of estrogen in regulating MK function and platelet production. More interestingly, the emerging picture underscores a clear role of estrogens and ERs as key regulators of platelet physiology and pathology. In particular, in this peculiar cell type, ER-associated signaling could be referred as to both mER and mtER and could be related to rapid signals leading to platelet function/dysfunction. The study of these receptors and their signaling
Conflict of interest
The authors report no relationships that could be construed as a conflict of interest.
References (104)
Mechanisms of hormonal therapy related thrombosis
Thromb. Res.
(2013)- et al.
Sex, thrombosis and inherited thrombophilia
Blood Rev.
(2014) - et al.
Lifetime estrogen exposure versus age at menopause as mortality predictor
Maturitas
(2002) - et al.
Risk factors for venous thromboembolism in pre-and postmenopausal women
Thromb. Res.
(2012) - et al.
Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients
Int. J. Cardiol.
(2014) - et al.
Childhood arterial ischaemic stroke incidence, presenting features, and risk factors: a prospective population-based study
Lancet Neurol.
(2014) - et al.
Determination of risk factors for deep venous thrombosis in hospitalized children
J. Pediatr. Surg.
(2008) - et al.
Sex difference in the effect of aspirin on intracellular Ca2 + mobilization and thromboxane A2 production in rat platelets
Jpn. J. Pharmacol.
(1986) - et al.
Gender difference in vascular and platelet reactivity to thromboxane A(2)-mimetic U46619 and to endothelial dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats
Diabetes Res. Clin. Pract.
(2003) Hormone therapy and venous thromboembolism
Best Pract. Res. Clin. Endocrinol. Metab.
(2003)
Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis
J. Steroid Biochem. Mol. Biol.
Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women
Maturitas
Hormone replacement therapy and venous thromboembolism
J. Steroid Biochem. Mol. Biol.
Signaling functions of ubiquitin in the 17β-estradiol (E2):estrogen receptor (ER) α network
J. Steroid Biochem. Mol. Biol.
Estrogen receptor α and β in the normal immune system and in lymphoid malignancies
Mol. Cell. Endocrinol.
Emerging evidence of the importance of rapid, non-nuclear estrogen receptor signaling in the cardiovascular system
Steroids
Mitochondrial estrogen receptors—new insights into specific functions
Trends Endocrinol. Metab.
Tumor suppressor p53 and estrogen receptors in nuclear–mitochondrial communication
Mitochondrion
Plasma membrane estrogen receptors
Trends Endocrinol. Metab.
Platelet count, mean platelet volume and thrombocytopoietic indices in healthy women and men
Thromb. Res.
Mechanisms of thrombopoiesis
J. Thromb. Haemost.
Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression
Blood
Dynamic combinatorial interactions of RUNX1 and cooperating partners regulates megakaryocytic differentiation in cell line models
Blood
Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase
Blood
Progesterone metabolites rapidly stimulate calcium influx in human platelets by a src-dependent pathway
Steroids
Tamoxifen promotes superoxide production in platelets by activation of PI3-kinase and NADPH oxidase pathways
Thromb. Res.
Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation
Blood
Estrogen receptor α promotes non-amyloidogenic processing of platelet amyloid precursor protein via the MAPK/ERK pathway
J. Steroid Biochem. Mol. Biol.
Membrane lipid rafts coordinate estrogen-dependent signaling in human platelets
Biochim. Biophys. Acta
Procoagulant platelets: are they necrotic?
Blood
MicroRNAs in hemostasis
J. Thromb. Haemost.
miRNAs and estrogen action
Trends Endocrinol. Metab.
MicroRNAs in platelet production and activation
J. Thromb. Haemost.
Gender differences in stroke incidence and poststroke disability in the Framingham heart study
Stroke
Sex difference in risk of second but not of first venous thrombosis: paradox explained
Circulation
Sexual dimorphism in ischemic stroke: lessons from the laboratory
Womens Health (Lond. Engl.)
Cardiovascular disease is preventable among women
Expert. Rev. Cardiovasc. Ther.
Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010
Eur. Heart J.
Analysis of gender-related differences in lower extremity peripheral arterial disease
J. Vasc. Surg.
Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen
Cardiovasc. Res.
Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms
Thromb. Haemost.
Thrombus composition in acute ischemic stroke: a histopathological study of thrombus extracted by endovascular retrieval
J. Neuroradiol.
Risk factors and stroke mechanisms in atherosclerotic stroke: intracranial compared with extracranial and anterior compared with posterior circulation disease
Stroke
Male predominance in childhood ischemic stroke: findings from the international pediatric stroke study
Stroke
Thrombosis formation on atherosclerotic lesions and plaque rupture
J. Intern. Med.
Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males
Arterioscler. Thromb. Vasc. Biol.
Gender differences in platelet aggregation in healthy individuals
J. Thromb. Thrombolysis
Gender differences in platelet GPIIb–IIIa activation
Thromb. Haemost.
Platelet hyperreactivity in women from families with premature atherosclerosis
J. Am. Med. Womens Assoc.
Haemostatic variables during normal menstrual cycle. A systematic review
Thromb. Haemost.
Cited by (20)
“Mind the gap” acute coronary syndrome in women: A contemporary review of current clinical evidence
2017, International Journal of CardiologyCitation Excerpt :There has been no convincing evidence that exogenous estrogens are beneficial in primary [45] or secondary [46] prevention of cardiovascular disease. A helpful review article looking at the relevance of the estrogen/estrogen receptor system on the gender difference in cardiovascular risk (including its interaction with platelets) was published by Del Principe et al. in 2015 [47]. In addition, Miller and Duckles performed a comprehensive review on the functional implications of the vascular actions of estrogens and their receptors [48].
Vascular Diseases in Women: Do Women Suffer from Them Differently?
2024, Journal of Clinical MedicineProfile of Injured Singers: Expectations and Insights
2022, LaryngoscopeDietary calcium, magnesium, and phosphorus intakes and risk of stroke in Chinese adults
2021, Scientific ReportsPulmonary thromboembolism during pregnancy and puerperium: Comparison of survival and death cases
2021, Journal of Obstetrics and Gynaecology Research
- 1
To be considered as senior authors.